Long-term, placebo-controlled trial of ketotifen in the management of preschool children with asthma*1

Loftus, B G; Price, John

doi:10.1016/0091-6749(87)90154-0

Cited by 32 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some previous trials have demonstrated the utility of ketotifen in asthmatic children [8,9], with possible clinical efficacy equivalent to cromoglycate [23]. On the other hand, certain trials have yielded disappointing results with ketotifen, particularly in children with more severe asthma who are being treated concurrently with other prophylactic medications, cromoglycate or inhaled steroids [24]. It would appear, therefore, that ketotifen and ICS do not have a synergistic effect, although this does not necessarily imply that ketotifen is not worthwhile in children who are dependent on higher doses of ICS in order to facilitate a reduction in daily steroid storage.…”

Section: Discussionmentioning

confidence: 99%

Does ketotifen have a steroid-sparing effect in childhood asthma?

Canny

Reisman²,

Levison³

1997

Eur Respir J

View full text Add to dashboard Cite

In view of the possible systemic side-effects of inhaled corticosteroids (ICS), a study was performed to determine whether ketotifen (versus placebo) can replace or allow a reduction in the dose of ICS required for the maintenance treatment of childhood asthma.Sixty six children (aged 6-13 yrs) with asthma (confirmed by methacholine challenge), who were maintained on ICS, at a dose of ≤1 mg·day -1 , were selected, and 52 subjects completed the trial. Children on long-term oral steroids or cromoglycate were excluded. After a 4 week baseline period, the children were randomized to receive ketotifen, 2 mg·day -1 , or placebo for 32 Weeks. Between weeks 13-20 of the study, the daily dose of steroid was tapered by 25% every second week to the minimum dose tolerated by the patients. For the remainder of the study (Weeks 21-32) the patients continued on this dose (if tolerated). Beta 2 -agonists were allowed, as necessary, for symptom relief During the baseline period, the mean daily ICS dosage was 432 µg in the ketotifen group versus 408 µg in the placebo group (NS). Among the patients who completed the study, the average ICS dosage during the final phase of the study (Weeks 21-32) was only 18% of baseline in the ketotifen group versus 35% in the placebo group (NS). Lung function, diurnal variability in peak flow rates and methacholine sensitivity (provocative concentration producing a 20% fall in forced expiratory volume in one second (PC20)) remained unchanged in both groups throughout the study. During the last 12 weeks of the study, the ketotifen-treated patients were symptomatically better controlled.In the present study, ketotifen did not have a greater steroid-sparing effect than placebo.

show abstract

Section: Discussionmentioning

confidence: 99%

Does ketotifen have a steroid-sparing effect in childhood asthma?

Canny

Reisman²,

Levison³

1997

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Effects of ketotifen, a first generation H 1 ‐specific receptor antagonist, seemed to be promising because of possible intrinsic anti‐inflammatory properties resulting in reduction of eosinophilic activation and migration, and normalization of β‐receptor expression thus preventing tachyphylaxis [ 130, 131]. Since then, many double‐blind, placebo‐controlled studies estimating clinical efficacy of ketotifen in asthma have been performed [ 131–151]. Overall, ketotifen (1 mg bid) seems to ameliorate asthma severity slightly (especially in children), with improvement of symptoms, rescue medication use and number of exacerbations.…”

Section: Other Drugs With Anti‐inflammatory Propertiesmentioning

confidence: 99%

Alternative strategies in the treatment of bronchial asthma

Veen

Sterk

Bel

2000

Clin Experimental Allergy

View full text Add to dashboard Cite

“…[86][87][88][89] thors reported beneficial effects in asthmatic children treated with this drug. [62][63][64][65] In a 7-month, doubleOxatomide was demonstrated in vitro to be effective in modulating T cell activation 90 and the release of blind, placebo-controlled Canadian multicenter study carried out in 138 asthmatic children aged from 5 to PAF 91 from neutrophils and to inhibit oxygen-radical generation and peptide-leukotriene release from eos-17 years, ketotifen determined an increase in FEV 1 and PEFR, and an improvement of symptom scores, inophils. Some capacity to interfere with the cysteinylleukotrienes release was also shown for ketotifen and and reduced the use of concomitant medications, the number of emergency visits and the incidence of upper azelastine.…”

mentioning

confidence: 97%

“…84,85 conducted. [62][63][64][65][66][67][68][69][70][71][72][73] Although one early study 6 failed to demonstrate an effect in children's asthma, other auCetirizine also is capable of reducing eosinophil survival in vitro and the chemotaxis for lymphocytes. [86][87][88][89] thors reported beneficial effects in asthmatic children treated with this drug.…”

mentioning

confidence: 99%